Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Frisaldi, Elisa [VerfasserIn]   i
 Vollert, Jan [VerfasserIn]   i
 Al Sultani, Husam [VerfasserIn]   i
 Benedetti, Fabrizio [VerfasserIn]   i
 Shaibani, Aziz [VerfasserIn]   i
Titel:Placebo and nocebo responses in painful diabetic neuropathy
Titelzusatz:systematic review and meta-analysis
Verf.angabe:Elisa Frisaldi, Jan Vollert, Husam Al Sultani, Fabrizio Benedetti, Aziz Shaibani
E-Jahr:2024
Jahr:January 2024
Umfang:15 S.
Fussnoten:Gesehen am 08.05.2024
Titel Quelle:Enthalten in: Pain
Ort Quelle:New York, NY [u.a.] : Lippincott Williams and Wilkins, 1975
Jahr Quelle:2024
Band/Heft Quelle:165(2024), 1 vom: Jan., Seite 29-43
ISSN Quelle:1872-6623
Abstract:This preregistered (CRD42021223379) systematic review and meta-analysis aimed to characterize the placebo and nocebo responses in placebo-controlled randomized clinical trials (RCTs) on painful diabetic neuropathy (PDN), updating the previous literature by a decade. Four databases were searched for PDN trials published in the past 20 years, testing oral medications, adopting a parallel-group design. Magnitude of placebo or nocebo responses, Cochrane risk of bias, heterogeneity, and moderators were evaluated. Searches identified 21 studies (2425 placebo-treated patients). The overall mean pooled placebo response was −1.54 change in the pain intensity from baseline [95% confidence interval (CI): −1.52, −1.56, I2 = 72], with a moderate effect size (Cohen d = 0.72). The pooled placebo 50% response rate was 25% [95% CI: 22, 29, I2 = 50%]. The overall percentage of patients with adverse events (AEs) in the placebo arms was 53.3% [95% CI: 50.9, 55.7], with 5.1% [95% CI: 4.2, 6] of patients dropping out due to AEs. The year of study initiation was the only significant moderator of placebo response (regression coefficient = −0.06, [95% CI: −0.10, −0.02, P = 0.007]). More recent RCTs tended to be longer, bigger, and to include older patients (N = 21, rs = 0.455, P = 0.038, rs = 0.600, P = 0.004, rs = 0.472, P = 0.031, respectively). Our findings confirm the magnitude of placebo and nocebo responses, identify the year of study initiation as the only significant moderator of placebo response, draw attention to contextual factors such as confidence in PDN treatments, patients' previous negative experiences, intervention duration, and information provided to patients before enrollment.
DOI:doi:10.1097/j.pain.0000000000003000
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1097/j.pain.0000000000003000
 Volltext: https://journals.lww.com/pain/fulltext/2024/01000/placebo_and_nocebo_responses_in_painful_diabetic.4.aspx
 DOI: https://doi.org/10.1097/j.pain.0000000000003000
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1888124423
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69212294   QR-Code
zum Seitenanfang